GLP-1 receptor agonists reduced a composite kidney outcome by 20% across 20 trials in type 2 diabetes

Design

Systematic review and random-effects meta-analysis of randomised placebo-controlled trials

Population

20 trials, 83,004 adults with type 2 diabetes

Primary outcome

MACE and component outcomes; composite renal outcome

Effect

Renal composite RR 0.80 (0.73 to 0.88); MACE RR 0.87 (0.83 to 0.92)

A meta-analysis pooled 20 placebo-controlled randomised trials of GLP-1 receptor agonists in 83,004 people with type 2 diabetes.

Against placebo, GLP-1 agonists reduced the composite kidney outcome (RR 0.80), major adverse cardiovascular events (0.87), all-cause death (0.89), cardiovascular death (0.88), myocardial infarction (0.87) and stroke (0.88). Heart failure admission (0.93) and coronary revascularisation (0.87) trended lower without reaching significance.

For nephrologists, the kidney composite is the point: GLP-1 agonists now sit alongside RAS blockade, SGLT2 inhibitors and finerenone as kidney-protective therapy in diabetes. In India, cost and gastrointestinal tolerability, particularly in patients with low body weight or poor intake, are the practical limits.

• Consider a GLP-1 agonist in type 2 diabetes with CKD, alongside RAS blockade and an SGLT2 inhibitor
• Check the label for dosing at low eGFR; most agents need no renal adjustment
• Warn about nausea and vomiting, which can cause volume depletion and acute kidney injury
• Monitor weight and nutrition in older or frail patients

Why it matters

Kidney protection in diabetes is now a four-drug conversation, not a two-drug one.

Don't overread it

Kidney composites in these trials were often secondary endpoints driven by albuminuria; hard kidney failure events were fewer.

The statistics, in plain English

A risk ratio of 0.80 (0.73 to 0.88) means about 20% fewer kidney composite events, with a precise interval from many trials. Composite kidney outcomes often include new macroalbuminuria, which responds more readily than dialysis or doubling of creatinine, so the benefit on hard end points may be smaller.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.